株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

軟部組織腫瘍(STS)市場の洞察、疫学、市場予測 2028年

Soft Tissue Sarcoma (STS) Market Insights, Epidemiology, and Market Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 534851
出版日 ページ情報 英文 440 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.54円で換算しております。
軟部組織腫瘍(STS)市場の洞察、疫学、市場予測 2028年 Soft Tissue Sarcoma (STS) Market Insights, Epidemiology, and Market Forecast - 2028
出版日: 2019年12月01日 ページ情報: 英文 440 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の軟部組織腫瘍(STS)の総有病数は2017年に40,155人、その市場規模は2億4,670万米ドル規模と推計されています。

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の軟部組織腫瘍(STS)市場を調査し、市場および疾患の概要、全体および国別の疫学的予測、セグメント別の罹患数の推移と予測、アンメットニーズ、上市済み治療薬および治験薬の概要、市場規模、成長要因および障壁の分析などについてまとめています。

目次

第1章 重要洞察

第2章 軟部組織腫瘍(STS):概要

  • 患者の分布状況(実数値)
  • 患者の分布状況(予測値)

第3章 疾患背景と概要:軟部組織腫瘍(STS)

  • イントロダクション
  • 軟部組織腫瘍(STS)の種類
  • 軟部組織腫瘍(STS)の分子構造
  • 軟部組織腫瘍(STS)の病期
  • 軟部組織腫瘍(STS)の診断
    • 病歴・身体検査
    • 画像検査
    • 生検
    • 病理診断
    • 診断ガイドライン

第4章 疫学と患者人口

  • 主な調査結果
  • 主要7カ国の軟部組織腫瘍(STS

第5章 軟部組織腫瘍(STS)の疫学:国別

  • 米国
    • 仮定と理論的根拠
    • 軟部組織腫瘍(STS)総罹患数
    • 軟部組織腫瘍(STS)罹患数:タイプ別
    • 消化管間質腫瘍(GIST)総罹患数
    • 消化管間質腫瘍(GIST)を含む軟部組織腫瘍(STS)の罹患数
    • 軟部組織腫瘍(STS)の罹患数:四肢別
  • EU5カ国
    • ドイツ
      • 仮定と理論的根拠
      • 軟部組織腫瘍(STS)総罹患数
      • 軟部組織腫瘍(STS)罹患数:タイプ別
      • 消化管間質腫瘍(GIST)総罹患数
      • 消化管間質腫瘍(GIST)を含む軟部組織腫瘍(STS)の罹患数
      • 軟部組織腫瘍(STS)の罹患数:四肢別
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本
    • 仮定と理論的根拠
    • 軟部組織腫瘍(STS)総罹患数
    • 軟部組織腫瘍(STS)罹患数:タイプ別
    • 消化管間質腫瘍(GIST)総罹患数
    • 消化管間質腫瘍(GIST)を含む軟部組織腫瘍(STS)の罹患数
    • 軟部組織腫瘍(STS)の罹患数:四肢別

第6章 軟部組織腫瘍(STS)の治療と管理

  • 病期別の治療法
  • 治療アルゴリズム
  • 治療ガイドライン

第7章 アンメットニーズ

第8章 上市済み治療薬

  • Halaven (Eribulin Mesylate):エーザイ
    • 製品概要
    • 規制マイルストーン
    • Gleevec (Imatinib Mesylate):Novartis
    • Yondelis (Trabectedin):Pharma Mar
    • Lartruvo (Olaratumab):Eli Lilly
    • Vitrakvi (Larotrectinib;BAY2757556):Bayer/Loxo Oncology
    • Stivarga (Regorafenib):Bayer
    • Sutent (Sunitinib malate):Pfizer
    • Votrient (Pazopanib):GlaxoSmithKline/Novartis
    • Vincristine Sulfate:Hospira
    • Rozlytrek (Entrectinib):Roche (Genentech)

第9章 新薬

  • キークロスコンペティション

第10章 第III相試験薬

  • Avapritinib (BLU-285):Blueprint Medicines Corporation
  • Vigil (In combination with irinotecan and temozolomide):Gradalis
  • Anlotinib (AL3818): Advenchen Laboratories/Jiangsu Chia-Tai Tianqing Pharmaceutical
  • Selinexor:Karyopharm Therapeutics
  • Aldoxorubicin (INNO-206):CytRx
  • Ripretinib (DCC-2618):Deciphera Pharmaceuticals
  • Fibromun (In combination with Doxorubicin):Philogen
  • Hensify (NBTXR3):Nanobiotix

第11章 第II相試験薬

  • GSK3377794:GlaxoSmithKline/Adaptimmune
  • ADP-A2M4: Adaptimmune
  • Tazemetostat (EPZ-6438): Epizyme
  • AMG 337: NantPharma/ Amgen
  • GB226/APL-501: Genor Biopharma/Apollomics
  • Camsirubicin:Monopar Therapeutics/Gem Pharmaceuticals
  • LTX-315:Lytix Biopharma
  • Abemaciclib (LY2835219):Eli Lilly and Company
  • Pembrolizumab: Merck Sharp & Dohme Corp.
  • Crizotinib (PF-02341066): Pfizer
  • ABI-009: Aadi Bioscience
  • Nivolumab: Bristol-Myers Squibb
  • Sorafenib Tosylate: Bayer
  • Doxorubicin with AGEN1884 and AGEN2034:Agenus
  • Apatinib Mesylate (In Combination with Doxorubicin and
  • Ifosfamide: Jiangsu HengRui Medicine
  • Atezolizumab: Roche Pharma AG
  • Spartalizumab (PDR001):Novartis Pharmaceuticals
  • Iclusig (Ponatinib):武田薬品
  • Temozolomide (Temodar):Merck
  • Cabozantinib:Exelixis
  • Avelumab:Merck KGaA

第12章 第1/II相試験薬

  • Lenvatinib (In Combination with Everolimus):エーザイ
  • SRA737:Sierra Oncology
  • Nab-paclitaxel:Celgene
  • Afatinib:Boehringer Ingelheim
  • IMCnyeso (GSK01):GlaxoSmithKline/Immunocore
  • CAR-T/TCR-T Cell Immunotherapy:Shenzhen BinDeBio
  • Epirubicin Micelle (NC-6300; K-912):NanoCarrier
  • Copanlisib (BAY806946): Bayer
  • PLX9486:Plexxikon
  • BA3021:BioAtla
  • Tinostamustine (EDO-S101): Mundipharma-EDO GmbH
  • TBI-1301 (NY-ESO-1 T cell Receptor Gene Transduced
  • Autologous T Lymphocytes):タカラバイオ
  • Ramucirumab (LY3009806):Eli Lilly and Company
  • TB-403:Oncurious NV
  • TLC178:Taiwan Liposome Company
  • Talimogene Laherparepvec (T-VEC):Amgen
  • MEK162:Array BioPharma
  • Neoadjuvant Durvalumab and Tremelimumab:AstraZeneca
  • Selpercatinib (LOXO-292):Eli Lilly/Loxo Oncology

第13章 腫瘍7カ国の軟部組織腫瘍(STS)市場の分析

  • 主な調査結果
  • 総市場規模
  • 市場規模:治療薬別

第14章 米国市場の見通し

  • 米国の軟部組織腫瘍(STS)市場の見通し
    • 総市場規模
    • 市場規模:治療薬別

第15章 欧州市場の見通し

  • ドイツ
    • 総市場規模
    • 市場規模:治療薬別
  • フランス
  • イタリア
  • スペイン
  • 英国

第16章 日本市場の見通し

  • 米国の軟部組織腫瘍(STS)市場の見通し
    • 総市場規模
    • 市場規模:治療薬別

第17章 市場の成長要因

第18章 市場の障壁

第19章 付録

  • 調査方法

第20章 DelveInsightのサービス内容

第21章 免責事項

第22章 DelveInsightについて

図表

List of Tables

  • Table 1 The IGF System in Sarcoma Pathogenesis
  • Table 2 Trunk and Extremities Sarcoma Stages
  • Table 3 Incident Patient Population of STS in the 7MM (2017-2028)
  • Table 4 Total Incident Population of STS in the United States (2017-2028)
  • Table 5 Type-Specific Incidence of STS in the US (2017-2028)
  • Table 6 Total Incident Population of GIST in the United States (2017-2028)
  • Table 7 Total Incident Population of STS including GIST in the United States (2017-2028)
  • Table 8 Gender-Specific Incidence of STS in the United States (2017-2028)
  • Table 9 Age-Specific Incidence of STS in the United States (2017-2028)
  • Table 10 Stage-Specific Incidence of STS in the United States (2017-2028)
  • Table 11 Incidence of STS* by Extremities (%) in the United States (2017-2028)
  • Table 12 Total Incident Population of STS in Germany (2017-2028)
  • Table 13 Gender-Specific Incidence of STS in Germany (2017-2028)
  • Table 14 Type-Specific Incidence of STS in Germany (2017-2028)
  • Table 15 Age-Specific Incidence of STS in Germany (2017-2028)
  • Table 16 Stage-Specific Incidence of STS in Germany (2017-2028)
  • Table 17 Incidence of STS by Extremities (%) in Germany (2017-2028)
  • Table 18 Total Incident Population of STS in France (2017-2028)
  • Table 19 Gender-Specific Incidence of STS in France (2017-2028)
  • Table 20 Type-Specific Incidence of STS in France (2017-2028)
  • Table 21 Age-Specific Incidence of STS in France (2017-2028)
  • Table 22 Stage-Specific Incidence of STS in France (2017-2028)
  • Table 23 Incidence of STS by Extremities (%) in France (2017-2028)
  • Table 24 Total Incident Population of STS in Italy (2017-2028)
  • Table 25 Gender-Specific Incidence of STS in Italy (2017-2028)
  • Table 26 Type-Specific Incidence of STS in Italy (2017-2028)
  • Table 27 Age-Specific Incidence of STS in Italy (2017-2028)
  • Table 28 Stage-Specific Incidence of STS in Italy (2017-2028)
  • Table 29 Incident of STS by Extremities (%) in Italy (2017-2028)
  • Table 30 Total Incident Population of STS in Spain (2017-2028)
  • Table 31 Gender-Specific Incidence of STS in Spain (2017-2028)
  • Table 32 Type-Specific Incidence of STS in Spain (2017-2028)
  • Table 33 Age-Specific Incidence of STS in Spain (2017-2028)
  • Table 34 Stage-Specific Incidence of STS in Spain (2017-2028)
  • Table 35 Incident of STS by Extremities (%) in Spain (2017-2028)
  • Table 36 Total Incident Population of STS in the United Kingdom (2017-2028)
  • Table 37 Gender-Specific Incidence of STS in the United Kingdom (2017-2028)
  • Table 38 Type-Specific Incidence of STS in the UK (2017-2028)
  • Table 39 Age-Specific Incidence of STS in the United Kingdom (2017-2028)
  • Table 40 Stage-Specific Incidence of STS in the United Kingdom (2017-2028)
  • Table 41 Incident of STS by Extremities (%) in the United Kingdom (2017-2028)
  • Table 42 Total Incident Population of STS in Japan (2017-2028)
  • Table 43 Gender-Specific Incidence of STS in Japan (2017-2028)
  • Table 44 Type-Specific Incidence of STS in Japan (2017-2028)
  • Table 45 Age-Specific Incidence of STS in Japan (2017-2028)
  • Table 46 Stage-Specific Incidence of STS in Japan (2017-2028)
  • Table 47 Incident of STS by Extremities (%) in Japan (2017-2028)
  • Table 48 Novel and Targeted Agents for the Treatment of Soft-Tissue Sarcomas
  • Table 49 Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America-United States Public Health Service Grading System)
  • Table 50 Recommended dressings for neonates with EB
  • Table 51 Marketed Drug analysis
  • Table 52 Halaven, Clinical Trial Description, 2019
  • Table 53 Halaven; Clinical Trial Description, 2019
  • Table 54 Gleevec (Imatinib Mesylate), Clinical Trial Description, 2019
  • Table 55 Yondelis (Trabectedin), Clinical Trial Description, 2019
  • Table 56 Lartruvo (Olaratumab); Clinical Trial Description, 2019
  • Table 57 Vitrakvi, Clinical Trial Description, 2019
  • Table 58 Stivarga, Clinical Trial Description, 2019
  • Table 59 Stivarga; Clinical Trial Description, 2019
  • Table 60 Sutent; Clinical Trial Description, 2019
  • Table 61 Pazopanib, Clinical Trial Description, 2019
  • Table 62 Pazopanib; Clinical Trial Description, 2019
  • Table 63 Emerging Key cross Competition
  • Table 64 Emerging Key cross Competition (continued)
  • Table 65 Avapritinib (BLU-285), Clinical Trial Description, 2019
  • Table 66 Vigil, Clinical Trial Description, 2019
  • Table 67 Anlotinib (AL3818), Clinical Trial Description, 2019
  • Table 68 Selinexor, Clinical Trial Description, 2019
  • Table 69 Aldoxorubicin, Clinical Trial Description, 2019
  • Table 70 DCC-2618, Clinical Trial Description, 2019
  • Table 71 Fibromun (L19TNF); Clinical Trial Description, 2019
  • Table 72 NBTXR3, Clinical Trial Description, 2019
  • Table 73 Crenolanib, Clinical Trial Description, 2019
  • Table 74 TAS-116, Clinical Trial Description, 2019
  • Table 75 GSK3377794, Clinical Trial Description, 2019
  • Table 76 ADP-A2M4, Clinical Trial Description, 2019
  • Table 77 Tazemetostat; Clinical Trial Description, 2019
  • Table 78 AMG 337; Clinical Trial Description, 2019
  • Table 79 APL-501/GB226, Clinical Trial Description, 2019
  • Table 80 Camsirubicin, Clinical Trial Description, 2019
  • Table 81 LTX-315; Clinical Trial Description, 2019
  • Table 82 LY2835219, Clinical Trial Description, 2019
  • Table 83 Keytruda in combination with other drugs for soft tissue sarcoma
  • Table 84 Pembrolizumab, Clinical Trial Description, 2019
  • Table 85 Crizotinib, Clinical Trial Description, 2019
  • Table 86 ABI-009, Clinical Trial Description, 2019
  • Table 87 Combinations of Nivolumab
  • Table 88 Nivolumab; Clinical Trial Description, 2019
  • Table 89 Sorafenib Tosylate, Clinical Trial Description, 2019
  • Table 90 Doxorubicin with AGEN1884 and AGEN2034; Clinical Trial Description, 2019
  • Table 91 Apatinib Mesylate (In Combination with Doxorubicin and Ifosfamide, Clinical Trial Description, 2019
  • Table 92 Atezolizumab, Clinical Trial Description, 2019
  • Table 93 PDR001, Clinical Trial Description, 2019
  • Table 94 Ponatinib, Clinical Trial Description, 2019
  • Table 95 Lenvatinib (In combination with Everolimus), Clinical Trial Description, 2019
  • Table 96 SRA737, Clinical Trial Description, 2019
  • Table 97 Nab-paclitaxel; Clinical Trial Description, 2019
  • Table 98 Afatinib; Clinical Trial Description, 2019
  • Table 99 IMCnyeso, Clinical Trial Description, 2019
  • Table 100 CAR-T/TCR-T Cell Immunotherapy, Clinical Trial Description, 2019
  • Table 101 NC 6300, Clinical Trial Description, 2019
  • Table 102 Copanlisib (BAY806946); Clinical Trial Description, 2019
  • Table 103 PLX9486+/-PLX3397; Clinical Trial Description, 2019
  • Table 104 BA3021; Clinical Trial Description, 2019
  • Table 105 Tinostamustine (EDO-S101); Clinical Trial Description, 2019
  • Table 106 TBI-1301; Clinical Trial Description, 2019
  • Table 107 Ramucirumab (LY3009806); Clinical Trial Description, 2019
  • Table 108 TB-403; Clinical Trial Description, 2019
  • Table 109 TLC178; Clinical Trial Description, 2019
  • Table 110 Talimogene Laherparepvec, Clinical Trial Description, 2019
  • Table 111 MEK162, Clinical Trial Description, 2019
  • Table 112 Neoadjuvant Durvalumab and Tremelimumab, Clinical Trial Description, 2019
  • Table 113 LOXO-292, Clinical Trial Description, 2019
  • Table 114 Market size of mSTS by Region in USD Million (2017-2028)
  • Table 115 Market Size of metastatic STS by Therapies in the 7MM, in USD Million (2017-2028)
  • Table 116 United States Market Size of mSTS* in USD Million (2017-2028)
  • Table 117 Market Size of metastatic STS by Therapies in the United States, in USD Million (2017-2028)
  • Table 118 Market Size of mSTS by First-line of Therapies in the US, in USD Million (2017-2028)
  • Table 119 Market Size of metastatic STS by Second-line & Later Line Therapies in the US, in USD Million (2017-2028)
  • Table 120 Market Size of mGIST in the United States, in USD Million (2017-2028)
  • Table 121 United States Market Size of mSTS including GIST in USD Million (2017-2028)
  • Table 122 Germany Market Size of STS in USD Million (2017-2028)
  • Table 123 Market Size of metastatic STS by Therapies in Germany, in USD Million (2017-2028)
  • Table 124 Market Size of STS by First-line of Therapies in Germany, in USD Million (2017-2028)
  • Table 125 Market Size of metastatic STS by Second-line and later on Therapies in Germany, in USD Million (2017-2028)
  • Table 126 France Market Size of STS in USD Million (2017-2028)
  • Table 127 Market Size of mSTS by Therapies in France, in USD Million (2017-2028)
  • Table 128 Market Size of mSTS by First-line of Therapies in France, in USD Million (2017-2028)
  • Table 129 Market Size of mSTS by Second-line and Later Line Therapies in France, in USD Million (2017-2028)
  • Table 130 Italy Market Size of mSTS in USD Million (2017-2028)
  • Table 131 Market Size of mSTS by Therapies in Italy, in USD Million (2017-2028)
  • Table 132 Market Size of mSTS by First-line of Therapies in Italy, in USD Million (2017-2028)
  • Table 133 Market Size of STS by Second-line and Later Line Therapies in Italy, in USD Million (2017-2028)
  • Table 134 Spain Market Size of mSTS in USD Million (2017-2028)
  • Table 135 Market Size of mSTS by Therapies in Spain, in USD Million (2017-2028)
  • Table 136 Market Size of mSTS by First-line of Therapies in Spain, in USD Million (2017-2028)
  • Table 137 Market Size of STS by Second-line and Later Line Therapies in Spain, in USD Million (2017-2028)
  • Table 138 United Kingdom Market Size of mSTS in USD Million (2017-2028)
  • Table 139 Market Size of mSTS by Therapies in the United Kingdom, in USD Million (2017-2028)
  • Table 140 Market Size of mSTS by First-line of Therapies in the UK, in USD Million (2017-2028)
  • Table 141 Market Size of STS by Second-line and Later Line Therapies in the UK, in USD Million (2017-2028)
  • Table 142 Japan Market Size of mSTS in USD Million (2017-2028)
  • Table 143 Market Size of mSTS by Therapies in Japan, in USD Million (2017-2028)
  • Table 144 Market Size of mSTS by First-line of Therapies in Japan, in USD Million (2017-2028)
  • Table 145 Market Size of STS by Second-line and Later Line Therapies in Japan, in USD Million (2017-2028)

List of Figures

  • Figure 1 Common Types of Soft-Tissue Sarcomas (STS)
  • Figure 2 Angiosarcoma
  • Figure 3 Dermatofibrosarcoma protuberans (DFSP)
  • Figure 4 Several Growth Factor Signals Activate Cell Membrane Receptor Tyrosine Kinases Leading to Activation of Downstream Interacting Signal Transduction Pathways (PI3K/AKT, RAF/MAPK, and mTOR)
  • Figure 5 Grade Numbers of Soft-Tissue Sarcoma (STS)
  • Figure 6 Diagnosis of Soft-Tissue Sarcoma
  • Figure 7 Imaging Tests for Soft-Tissue Sarcoma (STS)
  • Figure 8 Incidence of STS in the 7MM (2017-2028)
  • Figure 9 Total Incident Cases of STS in the United States (2017-2028)
  • Figure 10 Type-Specific Incidence of STS in the United States (2017-2028)
  • Figure 11 Total Incident Cases of GIST in the United States (2017-2028)
  • Figure 12 Total Incident Cases of STS including GIST in the United States (2017-2028)
  • Figure 13 Gender-Specific Incidence of STS in the United States (2017-2028)
  • Figure 14 Age-Specific Incidence of STS in the United States (2017-2028)
  • Figure 15 Stage-Specific Incidence of STS in the United States (2017-2028)
  • Figure 16 Incidence of STS* by Extremities (%) in the United States (2017-2028)
  • Figure 17 Total Incident Cases of STS in Germany (2017-2028)
  • Figure 18 Gender-Specific Incidence of STS in Germany (2017-2028)
  • Figure 19 Type-Specific Incident of STS in Germany (2017-2028)
  • Figure 20 Age-Specific Incidence of STS in Germany (2017-2028)
  • Figure 21 Stage-Specific Incidence of STS in Germany (2017-2028)
  • Figure 22 Incidence of STS by Extremities (%) in Germany (2017-2028)
  • Figure 23 Total Incident Cases of STS in France (2017-2028)
  • Figure 24 Gender-Specific Incidence of STS in France (2017-2028)
  • Figure 25 Type-Specific Incident of STS in France (2017-2028)
  • Figure 26 Age-Specific Incidence of STS in France (2017-2028)
  • Figure 27 Stage-Specific of STS in France (2017-2028)
  • Figure 28 Incidence of STS by Extremities (%) in France (2017-2028)
  • Figure 29 Total Incident Cases of STS in Italy (2017-2028)
  • Figure 30 Gender-Specific Incidence of STS in Italy (2017-2028)
  • Figure 31 Type-Specific Incident of STS in Italy (2017-2028)
  • Figure 32 Age-Specific Incidence of STS in Italy (2017-2028)
  • Figure 33 Stage-Specific Incidence of STS in Italy (2017-2028)
  • Figure 34 Incident of STS by Extremities (%) in Italy (2017-2028)
  • Figure 35 Total Incident Cases of STS in Spain (2017-2028)
  • Figure 36 Gender-Specific Incidence of STS in Spain (2017-2028)
  • Figure 37 Type-Specific Incident of STS in Spain (2017-2028)
  • Figure 38 Age-Specific Incidence of STS in Spain (2017-2028)
  • Figure 39 Stage-Specific Incidence of STS in Spain (2017-2028)
  • Figure 40 Incident of STS by Extremities (%) in Spain (2017-2028)
  • Figure 41 Total Incident Cases of STS in the United Kingdom (2017-2028)
  • Figure 42 Gender-Specific Incidence of STS in the United Kingdom (2017-2028)
  • Figure 43 Type-Specific Incident of STS in the United Kingdom (2017-2028)
  • Figure 44 Age-Specific Incidence of STS in the United Kingdom (2017-2028)
  • Figure 45 Stage-Specific Incidence of STS in the United Kingdom (2017-2028)
  • Figure 46 Incident of STS by Extremities (%) in the United Kingdom (2017-2028)
  • Figure 47 Total Incident Cases of STS in Japan (2017-2028)
  • Figure 48 Gender-Specific Incidence of STS in Japan (2017-2028)
  • Figure 49 Type-Specific Incident of STS in Japan (2017-2028)
  • Figure 50 Age-Specific Incidence of STS in Japan (2017-2028)
  • Figure 51 Stage-Specific Incidence of STS in Japan (2017-2028)
  • Figure 52 Incident of STS by Extremities (%) in Japan (2017-2028)
  • Figure 53 Management of Soft Tissue Sarcoma
  • Figure 54 Management of localized, clinically resectable STS
  • Figure 55 Management of advanced/metastatic, clinically unresectable STS
  • Figure 56 Treatment Algorithm of Advanced Liposarcoma
  • Figure 57 Treatment Algorithm of Advanced Soft Tissue Sarcoma
  • Figure 58 Treatment Algorithm of Advanced Leiomyosarcoma
  • Figure 59 Therapy algorithm for Undifferentiated Pleomorphic/Non-classifiable Sarcoma
  • Figure 60 Therapy algorithm for Advanced Angiosarcoma
  • Figure 61 Therapy algorithm for Advanced Synovial Sarcoma
  • Figure 62 Unmet Needs of Gastroparesis
  • Figure 63 Market size of metastatic Soft Tissue Sarcoma (STS) by Region in USD Million (2017-2028)
  • Figure 64 Market Size of mSTS by Therapies in 7MM, in USD Million (2017-2028)
  • Figure 65 United States Market Size of STS in USD Million (2017-2028)
  • Figure 66 Market Size of mSTS by Therapies in the United States in USD Million (2017-2028)
  • Figure 67 Market Size of metastatic STS by First-line of Therapies in the US, in USD Million (2017-2028)
  • Figure 68 Market Size of metastatic STS by Second-line and Later Line Therapies in the US, in USD Million (2017-2028)
  • Figure 69 Market Size of mGIST in the United States in USD Million (2017-2028)
  • Figure 70 United States Market Size of mSTS including GIST in USD Million (2017-2028)
  • Figure 71 Germany Market Size of STS in USD Million (2017-2028)
  • Figure 72 Market Size of STS by Therapies in Germany in USD Million (2017-2028)
  • Figure 73 Market Size of metastatic STS by First-line of Therapies in Germany, in USD Million (2017-2028)
  • Figure 74 Market Size of metastatic STS by Second-line and later on Therapies in Germany, in USD Million (2017-2028)
  • Figure 75 France Market Size of metastatic STS in USD Million (2017-2028)
  • Figure 76 Market Size of mSTS by Therapies in France in USD Million (2017-2028)
  • Figure 77 Market Size of mSTS by First-line of Therapies in France, in USD Million (2017-2028)
  • Figure 78 Market Size of mSTS by Second-line & Later Line Therapies in France, in USD Million (2017-2028)
  • Figure 79 Italy Market Size of mSTS in USD Million (2017-2028)
  • Figure 80 Market Size of mSTS by Therapies in Italy in USD Million (2017-2028)
  • Figure 81 Market Size of mSTS by First-line of Therapies in Italy, in USD Million (2017-2028)
  • Figure 82 Market Size of mSTS by Second-line & Later Line Therapies in Italy, in USD Million (2017-2028)
  • Figure 83 Spain Market Size of mSTS in USD Million (2017-2028)
  • Figure 84 Market Size of mSTS by Therapies in Spain in USD Million (2017-2028)
  • Figure 85 Market Size of mSTS by First-line of Therapies in Spain, in USD Million (2017-2028)
  • Figure 86 Market Size of mSTS by Second-line & Later Line Therapies in Spain, in USD Million (2017-2028)
  • Figure 87 United Kingdom Market Size of mSTS in USD Million (2017-2028)
  • Figure 88 Market Size of mSTS by Therapies in the UK in USD Million (2017-2028)
  • Figure 89 Market Size of mSTS by First-line of Therapies in the UK, in USD Million (2017-2028)
  • Figure 90 Market Size of mSTS by Second-line & Later Line Therapies in the UK, in USD Million (2017-2028)
  • Figure 91 Japan Market Size of mSTS in USD Million (2017-2028)
  • Figure 92 Market Size of mSTS by Therapies in Japan in USD Million (2017-2028)
  • Figure 93 Market Size of mSTS by First-line of Therapies in Japan, in USD Million (2017-2028)
  • Figure 94 Market Size of STS by Second-line & Later Line Therapies in Japan, in USD Million (2017-2028)
  • Figure 95 Market Drivers
  • Figure 96 Market Barriers
目次
Product Code: DIMI0217

DelveInsight's 'Soft Tissue Sarcoma (STS) - Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of STS in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

According to the World Health Organization (WHO), there are more than 50 histologic subtypes of STSs. The signs and symptoms of STSs vary greatly from patients to patients based on the type of STS. However, it is not associated with any noticeable symptoms early in the course of the disease but the affected individuals may notice slow-growing, painless mass in the affected area.

According to DelveInsight's, STS have various subtypes. It was observed that in the United States and European countries, liposarcoma and leiomyosarcoma were the most incident subtypes of STS, which contributed to majority of the cases. Whereas in Japan, subtypes, fibroblastic sarcomas and liposarcoma were more common.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Soft Tissue Sarcoma (STS) - Disease Understanding and Treatment Algorithm

Soft-tissue sarcoma (STS) are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). STSs may be classified according to the involved cell-type, the specific nature of the malignancy, and the disease's clinical course.

Soft Tissue Sarcoma (STS) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident Cases of Soft Tissue Sarcoma (STS) in the 7MM, Type-specific Incidence Cases of Soft Tissue Sarcoma (STS) in the 7MM, Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States, Total Incident Cases of STS including GIST in the United States and Incidence of STS by Extremities (%) in the 7MM scenario of STS in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight's, the total incident population of Soft Tissue Sarcoma (STS) in seven major markets was 40,155 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2028).

Among all the seven major markets, United States accounts for highest number of cases of STS. In 2017, there were 12,390 incident cases of STS-which did not included GIST cases-in the United States. The total incident cases of GIST which were observed in the United States in 2017 accounted for 5,090. This lead to the total incident population of STS to 17,480 in 2017.

Soft Tissue Sarcoma (STS) Drug Chapters

STS are a heterogeneous group of malignancies and relatively rare that are characterized by mesodermal differentiation. It is primarily encountered in adults but can affect patients of any age. There are many histologic subtypes, and the malignancy can be low or high grade. Soft tissue sarcoma treatments may include surgery, chemotherapy, radiation therapy, or a combination of these therapies.

The emerging therapies are classified into four categories based on their line of therapy. The upcoming first-line therapies that are going to be launched in the forecasted period includes, AL3818 (anlotinib), Fibromun. The second-line emerging therapies includes, Vigil in combination with irinotecan and temozolomide, AL3818, GSK 3377794, Ripretinib (DCC-2618), Tazemetostat, Abemaciclib, Pembrolizumab, Crizotinib, ABI-009, and SRA737. The third-line emerging therapies includes, Avapritinib, Cabozantinib, and Selinexor. The fourth-line emerging therapies includes Avapritinib, TAS-116, Crenolanib, and Ripretinib.

Soft Tissue Sarcoma (STS) Market Outlook

According to DelveInsight, the total market size of Soft Tissue Sarcoma (STS) excluding GIST in seven major markets was USD 246.7 million in 2017. The market size of STS is expected to increase at a significant CAGR during the study period (2017-2028).

Among all the seven major markets, United States accounts for highest market size of STS. In 2017, the market size of STS (excluding GIST) was found to be USD 142.18 million.

Soft Tissue Sarcoma (STS) Drugs Uptake

The current market size of STS is mainly attributed by Votrient, Yondelis, Halaven and various anthracycline and non-anthracycline regimens. The market size of GIST in the United States was found to be USD 119.7 million in 2017 and expected to increase during the forecast period (2019-2028), due to potential therapies Vitrakvi, Rozlytrek, Avapritinib, Ripretinib and others. Among EU5, Germany had the highest market size in 2017 with revenue USD 22.06 million followed by Italy with revenue USD 18.84 million. The market size of STS (excluding GIST) in Japan was found to be USD 17.60 million in 2017.

Soft Tissue Sarcoma (STS) Report Insights

  • Patient Population by total incident cases
  • Type-specific incident cases of STS
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Soft Tissue Sarcoma (STS) Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Soft Tissue Sarcoma (STS) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Soft Tissue Sarcoma (STS) market
  • Organize sales and marketing efforts by identifying the best opportunities for Soft Tissue Sarcoma (STS) market
  • To understand the future market competition in the Soft Tissue Sarcoma (STS) market.

Table of Contents

1. Key Insights

2. Soft-Tissue Sarcomas (STS) Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Soft-Tissue Sarcomas (STS) in 2017
  • 2.2. Market Share (%) Distribution of Soft-Tissue Sarcomas (STS) in 2028

3. Soft-Tissue Sarcomas (STS): Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Types of Soft-Tissue Sarcomas (STS)
  • 3.3. The Molecular Biology of Soft-Tissue Sarcomas (STS)
  • 3.4. Stages of Soft-Tissue Sarcomas (STS)
  • 3.5. Diagnosis of Soft-Tissue Sarcomas (STS)
    • 3.5.1. Medical History and Physical Exam
    • 3.5.2. Imaging Tests
    • 3.5.3. Biopsy
    • 3.5.4. Pathological diagnosis of soft tissue sarcomas
    • 3.5.5. Proposed Diagnostic Guidelines

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Incident Patient Population of Soft Tissue Sarcoma (STS)

5. Country Wise-Epidemiology of Soft Tissue Sarcoma (STS)

  • 5.1. United States Epidemiology
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in the United States
    • 5.1.3. Type-Specific Incidence of STS in the United States
    • 5.1.4. Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States
    • 5.1.5. Total Incident Cases of STS including GIST in the United States
    • 5.1.6. Incidence of STS by Extremities (%) in the United States
  • 5.2. EU5 Epidemiology
    • 5.2.1. Germany
      • 5.2.1.1. Assumptions and Rationale
      • 5.2.1.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Germany
      • 5.2.1.3. Gender-Specific Incidence of STS in Germany
      • 5.2.1.4. Type-Specific Incidence of STS in Germany
      • 5.2.1.5. Age-Specific Incidence of STS in Germany
      • 5.2.1.6. Stage-Specific Incidence of STS in Germany
      • 5.2.1.7. Incidence of STS by Extremities (%) in Germany
    • 5.2.2. France
      • 5.2.2.1. Assumptions and Rationale
      • 5.2.2.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in France
      • 5.2.2.3. Gender-Specific Incidence of STS in France
      • 5.2.2.4. Type-Specific Incidence of STS in France
      • 5.2.2.5. Age-Specific Incidence of STS in France
      • 5.2.2.6. Stage-Specific Diagnosed Incidence of STS in France
      • 5.2.2.7. Incidence of STS by Extremities (%) in France
    • 5.2.3. Italy
      • 5.2.3.1. Assumptions and Rationale
      • 5.2.3.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Italy
      • 5.2.3.3. Gender-Specific Incidence of STS in Italy
      • 5.2.3.4. Type-Specific Incidence of STS in Italy
      • 5.2.3.5. Age-Specific Incidence of STS in Italy
      • 5.2.3.6. Stage-Specific Diagnosed Incidence of STS in Italy
      • 5.2.3.7. Incident of STS by Extremities (%) in Italy
    • 5.2.4. Spain
      • 5.2.4.1. Assumptions and Rationale
      • 5.2.4.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Spain
      • 5.2.4.3. Gender-Specific Incidence of STS in Spain
      • 5.2.4.4. Type-Specific Incidence of STS in Spain
      • 5.2.4.5. Age-Specific Incidence of STS in Spain
      • 5.2.4.6. Stage-Specific Incidence of STS in Spain
      • 5.2.4.7. Incident of STS by Extremities (%) in Spain
    • 5.2.5. United Kingdom
      • 5.2.5.1. Assumptions and Rationale
      • 5.2.5.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in the United Kingdom
      • 5.2.5.3. Gender-Specific Incidence of STS in the United Kingdom
      • 5.2.5.4. Type-Specific Incidence of STS in the United Kingdom
      • 5.2.5.5. Age-Specific Incidence of STS in the United Kingdom
      • 5.2.5.6. Stage-Specific Diagnosed Incidence of STS in the United Kingdom
      • 5.2.5.7. Incident of STS by Extremities (%) in the United Kingdom
  • 5.3. Japan Epidemiology
    • 5.3.1. Assumptions and Rationale
    • 5.3.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Japan
    • 5.3.3. Gender-Specific Incidence of STS in Japan
    • 5.3.4. Type-Specific Incidence of STS in Japan
    • 5.3.5. Age-Specific Incidence of STS in Japan
    • 5.3.6. Stage-Specific Incidence of STS in Japan
    • 5.3.7. Incident of STS by Extremities (%) in Japan

6. Treatment and Management of Soft Tissue Sarcoma (STS)

  • 6.1. Stage-wise Treatment
  • 6.2. Treatment Algorithms
  • 6.3. Treatment Guidelines
    • 6.3.1. UK guidelines for the management of soft tissue sarcomas
    • 6.3.2. NCCN guidelines for the management of soft tissue sarcomas
    • 6.3.3. Soft Tissue and Visceral Sarcomas: ESMO-EURACAN Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up

7. Unmet Needs

8. Marketed Drugs

  • 8.1. Halaven (Eribulin Mesylate): Eisai
    • 8.1.1. Product Description
    • 8.1.2. Regulatory Milestones
    • 8.1.3. Clinical Development
    • 8.1.4. Ongoing Current Pipeline Activity
    • 8.1.5. Safety and efficacy
    • 8.1.6. Product Profile
  • 8.2. Gleevec (Imatinib Mesylate): Novartis
    • 8.2.1. Product Description
    • 8.2.2. Regulatory Milestones
    • 8.2.3. Clinical Development
    • 8.2.4. Safety and efficacy
    • 8.2.5. Product Profile
  • 8.3. Yondelis (Trabectedin): Pharma Mar
    • 8.3.1. Product Description
    • 8.3.2. Regulatory Milestones
    • 8.3.3. Clinical Development
    • 8.3.4. Safety and efficacy
    • 8.3.5. Product Profile
  • 8.4. Lartruvo (Olaratumab): Eli Lilly
    • 8.4.1. Product Description
    • 8.4.2. Regulatory Milestones
    • 8.4.3. Clinical Development
    • 8.4.4. Safety and efficacy
    • 8.4.5. Product Profile
  • 8.5. Vitrakvi (Larotrectinib; BAY2757556): Bayer/Loxo Oncology
    • 8.5.1. Product Description
    • 8.5.2. Regulatory Milestones
    • 8.5.3. Clinical Development
    • 8.5.4. Safety and efficacy
    • 8.5.5. Product Profile
  • 8.6. Stivarga (Regorafenib): Bayer
    • 8.6.1. Product Description
    • 8.6.2. Regulatory Milestones
    • 8.6.3. Clinical Development
    • 8.6.4. Ongoing Current Pipeline Activity
    • 8.6.5. Safety and efficacy
    • 8.6.6. Product Profile
  • 8.7. Sutent (Sunitinib malate): Pfizer
    • 8.7.1. Product Description
    • 8.7.2. Regulatory Milestones
    • 8.7.3. Clinical Development
    • 8.7.4. Safety and efficacy
    • 8.7.5. Product Profile
  • 8.8. Votrient (Pazopanib): GlaxoSmithKline/Novartis
    • 8.8.1. Product Description
    • 8.8.2. Regulatory Milestones
    • 8.8.3. Clinical Development
    • 8.8.4. Ongoing Current Pipeline Activity
    • 8.8.5. Safety and efficacy
    • 8.8.6. Product Profile
  • 8.9. Vincristine Sulfate: Hospira
    • 8.9.1. Product Description
    • 8.9.2. Regulatory Milestones
    • 8.9.3. Product Profile
  • 8.10. Rozlytrek (Entrectinib): Roche (Genentech)
    • 8.10.1. Product Description
    • 8.10.2. Regulatory Milestones
    • 8.10.3. Safety and Efficacy of Rozlytrek
    • 8.10.4. Clinical trial information
    • 8.10.5. Product Profile

9. Emerging Drugs

  • 9.1. Key Cross Competition

10. Phase III Emerging Molecules

  • 10.1. Avapritinib (BLU-285): Blueprint Medicines Corporation
    • 10.1.1. Product Description
    • 10.1.2. Other Development Activities
    • 10.1.3. Clinical Development
    • 10.1.4. Clinical Trials Information
    • 10.1.5. Safety and Efficacy
    • 10.1.6. Product Profile
  • 10.2. Vigil (In combination with irinotecan and temozolomide): Gradalis
    • 10.2.1. Product Description
    • 10.2.2. Other Development Activities
    • 10.2.3. Clinical Development
    • 10.2.4. Clinical Trials Information
    • 10.2.5. Safety and Efficacy
    • 10.2.6. Product Profile
  • 10.3. Anlotinib (AL3818): Advenchen Laboratories/Jiangsu Chia-Tai Tianqing Pharmaceutical
    • 10.3.1. Product Description
    • 10.3.2. Other Development Activities
    • 10.3.3. Clinical Development
    • 10.3.4. Clinical Trials Information
    • 10.3.5. Safety and Efficacy
    • 10.3.6. Product Profile
  • 10.4. Selinexor: Karyopharm Therapeutics
    • 10.4.1. Product Description
    • 10.4.2. Other Development Activities
    • 10.4.3. Clinical Development
    • 10.4.4. Clinical Trials Information
    • 10.4.5. Safety and Efficacy
    • 10.4.6. Product Profile
  • 10.5. Aldoxorubicin (INNO-206): CytRx
    • 10.5.1. Product Description
    • 10.5.2. Other Development Activities
    • 10.5.3. Clinical Development
    • 10.5.4. Clinical Trials Information
    • 10.5.5. Safety and Efficacy
    • 10.5.6. Product Profile
  • 10.6. Ripretinib (DCC-2618): Deciphera Pharmaceuticals
    • 10.6.1. Product Description
    • 10.6.2. Other Development Activities
    • 10.6.3. Clinical Development
    • 10.6.4. Clinical Trials Information
    • 10.6.5. Safety and Efficacy
    • 10.6.6. Product Profile
  • 10.7. Fibromun (In combination with Doxorubicin): Philogen
    • 10.7.1. Product Description
    • 10.7.2. Other Development Activities
    • 10.7.3. Clinical Development
    • 10.7.4. Clinical Trials Information
    • 10.7.5. Product Profile
  • 10.8. Hensify (NBTXR3): Nanobiotix
    • 10.8.1. Product Description
    • 10.8.2. Other Development Activities
    • 10.8.3. Clinical Development
    • 10.8.4. Clinical Trials Information
    • 10.8.5. Safety and efficacy
    • 10.8.6. Product Profile
  • 10.9. Crenolanib: Arog Pharmaceuticals
    • 10.9.1. Product Description
    • 10.9.2. Other Development Activities
    • 10.9.3. Clinical Development
    • 10.9.4. Clinical Trials Information
    • 10.9.5. Safety and Efficacy
    • 10.9.6. Product Profile
  • 10.10. TAS-116: Taiho Pharmaceutical
    • 10.10.1. Product Description
    • 10.10.2. Clinical Development
    • 10.10.3. Clinical Trials Information
    • 10.10.4. Safety and Efficacy
    • 10.10.5. Product Profile

11. Phase II Emerging Molecules

  • 11.1. GSK3377794: GlaxoSmithKline/ Adaptimmune
    • 11.1.1. Product Description
    • 11.1.2. Other Development Activities
    • 11.1.3. Clinical Development
    • 11.1.4. Clinical Trials Information
    • 11.1.5. Safety and Efficacy
    • 11.1.6. Product Profile
  • 11.2. ADP-A2M4: Adaptimmune
    • 11.2.1. Product Description
    • 11.2.2. Other Development Activities
    • 11.2.3. Clinical Development
    • 11.2.4. Clinical Trials Information
    • 11.2.5. Safety and Efficacy
    • 11.2.6. Product Profile
  • 11.3. Tazemetostat (EPZ-6438): Epizyme
    • 11.3.1. Product Description
    • 11.3.2. Other Developmental Activities
    • 11.3.3. Clinical Development
    • 11.3.4. Clinical Trials Information
    • 11.3.5. Safety and Efficacy
    • 11.3.6. Product Profile
  • 11.4. AMG 337: NantPharma/ Amgen
    • 11.4.1. Product Description
    • 11.4.2. Other Development Activities
    • 11.4.3. Clinical Development
    • 11.4.4. Clinical Trials Information
    • 11.4.5. Safety and Efficacy
    • 11.4.6. Product Profile
  • 11.5. GB226/APL-501: Genor Biopharma /Apollomics (Previously CBT Pharmaceuticals)
    • 11.5.1. Product Description
    • 11.5.2. Other Development Activities
    • 11.5.3. Clinical Development
    • 11.5.4. Clinical Trials Information
    • 11.5.5. Product Profile
  • 11.6. Camsirubicin: Monopar Therapeutics /Gem Pharmaceuticals
    • 1.1.1. Product Description
    • 1.1.2. Other Development Activities
    • 1.1.3. Clinical Development
    • 1.1.4. Clinical Trials Information
    • 1.1.5. Safety and Efficacy
    • 1.1.6. Product Profile
  • 1.2. LTX-315: Lytix Biopharma
    • 1.2.1. Product Description
    • 1.2.2. Other Development Activities
    • 1.2.3. Clinical Development
    • 1.2.4. Clinical Trials Information
    • 1.2.5. Safety and Efficacy
    • 1.2.6. Product Profile
  • 1.3. Abemaciclib (LY2835219): Eli Lilly and Company
    • 1.3.1. Product Description
    • 1.3.2. Other Development Activities
    • 1.3.3. Clinical Development
    • 1.3.4. Clinical Trials Information
    • 1.3.5. Safety and Efficacy
    • 1.3.6. Product Profile
  • 1.4. Pembrolizumab: Merck Sharp & Dohme Corp.
    • 1.4.1. Product Description
    • 1.4.2. Other Development Activities
    • 1.4.3. Clinical Development
    • 1.4.4. Clinical Trials Information
    • 1.4.5. Safety and Efficacy
    • 1.4.6. Product Profile
  • 1.5. Crizotinib (PF-02341066): Pfizer
    • 1.5.1. Product Description
    • 1.5.2. Other Development Activities
    • 1.5.3. Clinical Development
    • 1.5.4. Clinical Trials Information
    • 1.5.5. Safety and Efficacy
    • 1.5.6. Product Profile
  • 1.6. ABI-009: Aadi Bioscience
    • 1.6.1. Product Description
    • 1.6.2. Other Development Activities
    • 1.6.3. Clinical Development
    • 1.6.4. Clinical Trials Information
    • 1.6.5. Safety and Efficacy
    • 1.6.6. Product Profile
  • 1.7. Nivolumab: Bristol-Myers Squibb
    • 1.7.1. Product Description
    • 1.7.2. Other Development Activities
    • 1.7.3. Clinical Development
    • 1.7.4. Clinical Trials Information
    • 1.7.5. Safety and Efficacy
    • 1.7.6. Product Profile
  • 1.8. Sorafenib Tosylate: Bayer
    • 1.8.1. Product Description
    • 1.8.2. Clinical Development
    • 1.8.3. Clinical Trials Information
    • 1.8.4. Safety and Efficacy
    • 1.8.5. Product Profile
  • 1.9. Doxorubicin with AGEN1884 and AGEN2034: Agenus
    • 1.9.1. Product Description
    • 1.9.2. Clinical Development
    • 1.9.3. Clinical Trials Information
    • 1.9.4. Product Profile
  • 1.10. Apatinib Mesylate (In Combination with Doxorubicin and Ifosfamide: Jiangsu HengRui Medicine
    • 1.10.1. Product Description
    • 1.10.2. Clinical Development
    • 1.10.3. Clinical Trials Information
    • 1.10.4. Product Profile
  • 1.11. Atezolizumab: Roche Pharma AG
    • 1.11.1. Product Description
    • 1.11.2. Clinical Development
    • 1.11.3. Clinical Trials Information
    • 1.11.4. Product Profile
  • 1.12. Spartalizumab (PDR001): Novartis Pharmaceuticals
    • 1.12.1. Product Description
    • 1.12.2. Other Development Activities
    • 1.12.3. Clinical Development
    • 1.12.4. Clinical Trials Information
    • 1.12.5. Product Profile
  • 1.13. Iclusig (Ponatinib): Takeda
    • 1.13.1. Product Description
    • 1.13.2. Other Development Activities
    • 1.13.3. Clinical Development
    • 1.13.4. Clinical Trials Information
    • 1.13.5. Safety and Efficacy
    • 1.13.6. Product Profile
  • 1.14. Temozolomide (Temodar): Merck
    • 1.14.1. Product Description
    • 1.14.2. Other Developmental Activities:
    • 1.14.3. Clinical Development
    • 1.14.4. Clinical trial information
    • 1.14.5. Product Profile
  • 1.15. Cabozantinib: Exelixis
    • 1.15.1. Product Description
    • 1.15.2. Other Developmental Activities:
    • 1.15.3. Clinical Development
    • 1.15.4. Clinical trial information
    • 1.15.5. Safety and Efficacy
    • 1.15.6. Product Profile
  • 1.16. Avelumab: Merck KGaA
    • 1.16.1. Product Description
    • 1.16.2. Other Developmental Activities:
    • 1.16.3. Clinical Development
    • 1.16.4. Clinical trial information
    • 1.16.5. Product Profile

2. Phase I/II Emerging Molecules

  • 2.1. Lenvatinib (In Combination with Everolimus): Eisai
    • 2.1.1. Product Description
    • 2.1.2. Other Development Activities
    • 2.1.3. Clinical Development
    • 2.1.4. Clinical Trials Information
    • 2.1.5. Product Profile
  • 2.2. SRA737: Sierra Oncology
    • 2.2.1. Product Description
    • 2.2.2. Other Development Activities
    • 2.2.3. Clinical Development
    • 2.2.4. Clinical Trials Information
    • 2.2.5. Safety and Efficacy
    • 2.2.6. Product Profile
  • 2.3. Nab-paclitaxel: Celgene
    • 2.3.1. Product Description
    • 2.3.2. Other Developmental Activities
    • 2.3.3. Clinical Development
    • 2.3.4. Clinical Trials Information
    • 2.3.5. Safety and Efficacy
    • 2.3.6. Product Profile
  • 2.4. Afatinib: Boehringer Ingelheim
    • 2.4.1. Product Description
    • 2.4.2. Other Development Activities
    • 2.4.3. Clinical Development
    • 2.4.4. Clinical Trials Information
    • 2.4.5. Safety and Efficacy
    • 2.4.6. Product Profile
  • 2.5. IMCnyeso (GSK01): GlaxoSmithKline/Immunocore
    • 2.5.1. Product Description
    • 2.5.2. Other Development Activities
    • 2.5.3. Clinical Development
    • 2.5.4. Clinical Trials Information
    • 2.5.5. Product Profile
  • 2.6. CAR-T/TCR-T Cell Immunotherapy: Shenzhen BinDeBio
    • 2.6.1. Product Description
    • 2.6.2. Other Development Activities
    • 2.6.3. Clinical Development
    • 2.6.4. Clinical Trials Information
    • 2.6.5. Product Profile
  • 2.7. Epirubicin Micelle (NC-6300; K-912): NanoCarrier
    • 2.7.1. Product Description
    • 2.7.2. Other Development Activities
    • 2.7.3. Clinical Development
    • 2.7.4. Clinical Trials Information
    • 2.7.5. Safety and Efficacy
    • 2.7.6. Product Profile
  • 2.8. Copanlisib (BAY806946): Bayer
    • 2.8.1. Product Description
    • 2.8.2. Other Developmental Activities
    • 2.8.3. Clinical Development
    • 2.8.4. Clinical Trials Information
    • 2.8.5. Product Profile
  • 2.9. PLX9486: Plexxikon
    • 2.9.1. Product Description
    • 2.9.2. Clinical Development
    • 2.9.3. Clinical Trials Information
    • 2.9.4. Safety and Efficacy
    • 2.9.5. Product Profile
  • 2.10. BA3021: BioAtla
    • 2.10.1. Product Description
    • 2.10.2. Other Developmental Activities
    • 2.10.3. Clinical Development
    • 2.10.4. Clinical Trials Information
    • 2.10.5. Product Profile
  • 2.11. Tinostamustine (EDO-S101): Mundipharma-EDO GmbH
    • 2.11.1. Product Description
    • 2.11.2. Other Developmental Activities
    • 2.11.3. Clinical Development
    • 2.11.4. Clinical Trials Information
    • 2.11.5. Safety and Efficacy
    • 2.11.6. Product Profile
  • 2.12. TBI-1301 (NY-ESO-1 T cell Receptor Gene Transduced Autologous T Lymphocytes): Takara Bio.
    • 2.12.1. Product Description
    • 2.12.2. Other Developmental Activities
    • 2.12.3. Clinical Development
    • 2.12.4. Clinical Trials Information
    • 2.12.5. Safety and Efficacy
    • 2.12.6. Product Profile
  • 2.13. Ramucirumab (LY3009806): Eli Lilly and Company
    • 2.13.1. Product Description
    • 2.13.2. Clinical Development
    • 2.13.3. Clinical Trials Information
    • 2.13.4. Product Profile
  • 2.14. TB-403: Oncurious NV
    • 2.14.1. Product Description
    • 2.14.2. Other Developmental Activities
    • 2.14.3. Clinical Development
    • 2.14.4. Clinical Trials Information
    • 2.14.5. Product Profile
  • 2.15. TLC178: Taiwan Liposome Company
    • 2.15.1. Product Description
    • 2.15.2. Other Development Activities
    • 2.15.3. Clinical Development
    • 2.15.4. Clinical Trials Information
    • 2.15.5. Safety and Efficacy
    • 2.15.6. Product Profile
  • 2.16. Talimogene Laherparepvec (T-VEC): Amgen
    • 2.16.1. Product Description
    • 2.16.2. Other Developmental Activities
    • 2.16.3. Clinical Development
    • 2.16.4. Clinical Trials Information
    • 2.16.5. Safety and Efficacy
    • 2.16.6. Product Profile
  • 2.17. MEK162: Array BioPharma
    • 2.17.1. Product Description
    • 2.17.2. Clinical Development
    • 2.17.3. Clinical Trials Information
    • 2.17.4. Safety and Efficacy
    • 2.17.5. Product Profile
  • 2.18. Neoadjuvant Durvalumab and Tremelimumab: AstraZeneca
    • 2.18.1. Product Description
    • 2.18.2. Clinical Development
    • 2.18.3. Clinical Trials Information
    • 2.18.4. Safety and Efficacy
    • 2.18.5. Product Profile
  • 2.19. Selpercatinib (LOXO-292): Eli Lilly/Loxo Oncology
    • 2.19.1. Product Description
    • 2.19.2. Other Development Activities
    • 2.19.3. Clinical Development
    • 2.19.4. Clinical Trials Information
    • 2.19.5. Product Profile

3. Soft Tissue Sarcoma (STS): 7 Major Market Analysis

  • 3.1. Key Findings
  • 3.2. Market Size of metastatic Soft Tissue Sarcoma (STS) in the 7MM
  • 3.3. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in the 7MM

4. Market Outlook: The United States

  • 4.1. United States Market Size
    • 4.1.1. Total market size of Soft Tissue Sarcoma (STS)*
    • 4.1.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in the United States

5. Market Outlook: Europe

  • 5.1. Germany
    • 5.1.1. The total market size of Soft Tissue Sarcoma (STS)
    • 5.1.2. Market Size of Soft Tissue Sarcoma (STS) by Therapies in Germany
  • 5.2. France
    • 5.2.1. Total Market size of Soft Tissue Sarcoma (STS)
    • 5.2.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in France
  • 5.3. Italy
    • 5.3.1. Total Market size of Soft Tissue Sarcoma (STS)
    • 5.3.2. Market Size of Soft Tissue Sarcoma (STS) by Therapies in Italy
  • 5.4. Spain
    • 5.4.1. Total Market size of metastatic Soft Tissue Sarcoma (STS)
    • 5.4.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in Spain
  • 5.5. United Kingdom
    • 5.5.1. Total Market size of metastatic Soft Tissue Sarcoma (STS)
    • 5.5.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in the United Kingdom (UK)

6. Market Outlook: Japan

  • 6.1. Total Market size of metastatic Soft Tissue Sarcoma (STS)
  • 6.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in Japan
    • 6.2.1. Market Size of metastatic Soft Tissue Sarcoma (STS) by First-line of Therapies in Japan
    • 6.2.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Second-Line & Later Line Therapies in Japan

7. Market Drivers

8. Market Barriers

9. Appendix

  • 9.1. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

    • 11.6.1. Product Description
    • 11.6.2. Other Development Activities
    • 11.6.3. Clinical Development
    • 11.6.4. Clinical Trials Information
    • 11.6.5. Safety and Efficacy
    • 11.6.6. Product Profile
  • 11.7. LTX-315: Lytix Biopharma
    • 11.7.1. Product Description
    • 11.7.2. Other Development Activities
    • 11.7.3. Clinical Development
    • 11.7.4. Clinical Trials Information
    • 11.7.5. Safety and Efficacy
    • 11.7.6. Product Profile
  • 11.8. Abemaciclib (LY2835219): Eli Lilly and Company
    • 11.8.1. Product Description
    • 11.8.2. Other Development Activities
    • 11.8.3. Clinical Development
    • 11.8.4. Clinical Trials Information
    • 11.8.5. Safety and Efficacy
    • 11.8.6. Product Profile
  • 11.9. Pembrolizumab: Merck Sharp & Dohme Corp.
    • 11.9.1. Product Description
    • 11.9.2. Other Development Activities
    • 11.9.3. Clinical Development
    • 11.9.4. Clinical Trials Information
    • 11.9.5. Safety and Efficacy
    • 11.9.6. Product Profile
  • 11.10. Crizotinib (PF-02341066): Pfizer
    • 11.10.1. Product Description
    • 11.10.2. Other Development Activities
    • 11.10.3. Clinical Development
    • 11.10.4. Clinical Trials Information
    • 11.10.5. Safety and Efficacy
    • 11.10.6. Product Profile
  • 11.11. ABI-009: Aadi Bioscience
    • 11.11.1. Product Description
    • 11.11.2. Other Development Activities
    • 11.11.3. Clinical Development
    • 11.11.4. Clinical Trials Information
    • 11.11.5. Safety and Efficacy
    • 11.11.6. Product Profile
  • 11.12. Nivolumab: Bristol-Myers Squibb
    • 11.12.1. Product Description
    • 11.12.2. Other Development Activities
    • 11.12.3. Clinical Development
    • 11.12.4. Clinical Trials Information
    • 11.12.5. Safety and Efficacy
    • 11.12.6. Product Profile
  • 11.13. Sorafenib Tosylate: Bayer
    • 11.13.1. Product Description
    • 11.13.2. Clinical Development
    • 11.13.3. Clinical Trials Information
    • 11.13.4. Safety and Efficacy
    • 11.13.5. Product Profile
  • 11.14. Doxorubicin with AGEN1884 and AGEN2034: Agenus
    • 11.14.1. Product Description
    • 11.14.2. Clinical Development
    • 11.14.3. Clinical Trials Information
    • 11.14.4. Product Profile
  • 11.15. Apatinib Mesylate (In Combination with Doxorubicin and Ifosfamide: Jiangsu HengRui Medicine
    • 11.15.1. Product Description
    • 11.15.2. Clinical Development
    • 11.15.3. Clinical Trials Information
    • 11.15.4. Product Profile
  • 11.16. Atezolizumab: Roche Pharma AG
    • 11.16.1. Product Description
    • 11.16.2. Clinical Development
    • 11.16.3. Clinical Trials Information
    • 11.16.4. Product Profile
  • 11.17. Spartalizumab (PDR001): Novartis Pharmaceuticals
    • 11.17.1. Product Description
    • 11.17.2. Other Development Activities
    • 11.17.3. Clinical Development
    • 11.17.4. Clinical Trials Information
    • 11.17.5. Product Profile
  • 11.18. Iclusig (Ponatinib): Takeda
    • 11.18.1. Product Description
    • 11.18.2. Other Development Activities
    • 11.18.3. Clinical Development
    • 11.18.4. Clinical Trials Information
    • 11.18.5. Safety and Efficacy
    • 11.18.6. Product Profile
  • 11.19. Temozolomide (Temodar): Merck
    • 11.19.1. Product Description
    • 11.19.2. Other Developmental Activities:
    • 11.19.3. Clinical Development
    • 11.19.4. Clinical trial information
    • 11.19.5. Product Profile
  • 11.20. Cabozantinib: Exelixis
    • 11.20.1. Product Description
    • 11.20.2. Other Developmental Activities:
    • 11.20.3. Clinical Development
    • 11.20.4. Clinical trial information
    • 11.20.5. Safety and Efficacy
    • 11.20.6. Product Profile
  • 11.21. Avelumab: Merck KGaA
    • 11.21.1. Product Description
    • 11.21.2. Other Developmental Activities:
    • 11.21.3. Clinical Development
    • 11.21.4. Clinical trial information
    • 11.21.5. Product Profile

12. Phase I/II Emerging Molecules

  • 12.1. Lenvatinib (In Combination with Everolimus): Eisai
    • 12.1.1. Product Description
    • 12.1.2. Other Development Activities
    • 12.1.3. Clinical Development
    • 12.1.4. Clinical Trials Information
    • 12.1.5. Product Profile
  • 12.2. SRA737: Sierra Oncology
    • 12.2.1. Product Description
    • 12.2.2. Other Development Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Clinical Trials Information
    • 12.2.5. Safety and Efficacy
    • 12.2.6. Product Profile
  • 12.3. Nab-paclitaxel: Celgene
    • 12.3.1. Product Description
    • 12.3.2. Other Developmental Activities
    • 12.3.3. Clinical Development
    • 12.3.4. Clinical Trials Information
    • 12.3.5. Safety and Efficacy
    • 12.3.6. Product Profile
  • 12.4. Afatinib: Boehringer Ingelheim
    • 12.4.1. Product Description
    • 12.4.2. Other Development Activities
    • 12.4.3. Clinical Development
    • 12.4.4. Clinical Trials Information
    • 12.4.5. Safety and Efficacy
    • 12.4.6. Product Profile
  • 12.5. IMCnyeso (GSK01): GlaxoSmithKline/Immunocore
    • 12.5.1. Product Description
    • 12.5.2. Other Development Activities
    • 12.5.3. Clinical Development
    • 12.5.4. Clinical Trials Information
    • 12.5.5. Product Profile
  • 12.6. CAR-T/TCR-T Cell Immunotherapy: Shenzhen BinDeBio
    • 12.6.1. Product Description
    • 12.6.2. Other Development Activities
    • 12.6.3. Clinical Development
    • 12.6.4. Clinical Trials Information
    • 12.6.5. Product Profile
  • 12.7. Epirubicin Micelle (NC-6300; K-912): NanoCarrier
    • 12.7.1. Product Description
    • 12.7.2. Other Development Activities
    • 12.7.3. Clinical Development
    • 12.7.4. Clinical Trials Information
    • 12.7.5. Safety and Efficacy
    • 12.7.6. Product Profile
  • 12.8. Copanlisib (BAY806946): Bayer
    • 12.8.1. Product Description
    • 12.8.2. Other Developmental Activities
    • 12.8.3. Clinical Development
    • 12.8.4. Clinical Trials Information
    • 12.8.5. Product Profile
  • 12.9. PLX9486: Plexxikon
    • 12.9.1. Product Description
    • 12.9.2. Clinical Development
    • 12.9.3. Clinical Trials Information
    • 12.9.4. Safety and Efficacy
    • 12.9.5. Product Profile
  • 12.10. BA3021: BioAtla
    • 12.10.1. Product Description
    • 12.10.2. Other Developmental Activities
    • 12.10.3. Clinical Development
    • 12.10.4. Clinical Trials Information
    • 12.10.5. Product Profile
  • 12.11. Tinostamustine (EDO-S101): Mundipharma-EDO GmbH
    • 12.11.1. Product Description
    • 12.11.2. Other Developmental Activities
    • 12.11.3. Clinical Development
    • 12.11.4. Clinical Trials Information
    • 12.11.5. Safety and Efficacy
    • 12.11.6. Product Profile
  • 12.12. TBI-1301 (NY-ESO-1 T cell Receptor Gene Transduced Autologous T Lymphocytes): Takara Bio.
    • 12.12.1. Product Description
    • 12.12.2. Other Developmental Activities
    • 12.12.3. Clinical Development
    • 12.12.4. Clinical Trials Information
    • 12.12.5. Safety and Efficacy
    • 12.12.6. Product Profile
  • 12.13. Ramucirumab (LY3009806): Eli Lilly and Company
    • 12.13.1. Product Description
    • 12.13.2. Clinical Development
    • 12.13.3. Clinical Trials Information
    • 12.13.4. Product Profile
  • 12.14. TB-403: Oncurious NV
    • 12.14.1. Product Description
    • 12.14.2. Other Developmental Activities
    • 12.14.3. Clinical Development
    • 12.14.4. Clinical Trials Information
    • 12.14.5. Product Profile
  • 12.15. TLC178: Taiwan Liposome Company
    • 12.15.1. Product Description
    • 12.15.2. Other Development Activities
    • 12.15.3. Clinical Development
    • 12.15.4. Clinical Trials Information
    • 12.15.5. Safety and Efficacy
    • 12.15.6. Product Profile
  • 12.16. Talimogene Laherparepvec (T-VEC): Amgen
    • 12.16.1. Product Description
    • 12.16.2. Other Developmental Activities
    • 12.16.3. Clinical Development
    • 12.16.4. Clinical Trials Information
    • 12.16.5. Safety and Efficacy
    • 12.16.6. Product Profile
  • 12.17. MEK162: Array BioPharma
    • 12.17.1. Product Description
    • 12.17.2. Clinical Development
    • 12.17.3. Clinical Trials Information
    • 12.17.4. Safety and Efficacy
    • 12.17.5. Product Profile
  • 12.18. Neoadjuvant Durvalumab and Tremelimumab: AstraZeneca
    • 12.18.1. Product Description
    • 12.18.2. Clinical Development
    • 12.18.3. Clinical Trials Information
    • 12.18.4. Safety and Efficacy
    • 12.18.5. Product Profile
  • 12.19. Selpercatinib (LOXO-292): Eli Lilly/Loxo Oncology
    • 12.19.1. Product Description
    • 12.19.2. Other Development Activities
    • 12.19.3. Clinical Development
    • 12.19.4. Clinical Trials Information
    • 12.19.5. Product Profile

13. Soft Tissue Sarcoma (STS): 7 Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Market Size of metastatic Soft Tissue Sarcoma (STS) in the 7MM
  • 13.3. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in the 7MM

14. Market Outlook: The United States

  • 14.1. United States Market Size
    • 14.1.1. Total market size of Soft Tissue Sarcoma (STS)*
    • 14.1.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in the United States

15. Market Outlook: Europe

  • 15.1. Germany
    • 15.1.1. The total market size of Soft Tissue Sarcoma (STS)
    • 15.1.2. Market Size of Soft Tissue Sarcoma (STS) by Therapies in Germany
  • 15.2. France
    • 15.2.1. Total Market size of Soft Tissue Sarcoma (STS)
    • 15.2.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in France
  • 15.3. Italy
    • 15.3.1. Total Market size of Soft Tissue Sarcoma (STS)
    • 15.3.2. Market Size of Soft Tissue Sarcoma (STS) by Therapies in Italy
  • 15.4. Spain
    • 15.4.1. Total Market size of metastatic Soft Tissue Sarcoma (STS)
    • 15.4.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in Spain
  • 15.5. United Kingdom
    • 15.5.1. Total Market size of metastatic Soft Tissue Sarcoma (STS)
    • 15.5.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in the United Kingdom (UK)

16. Market Outlook: Japan

  • 16.1. Total Market size of metastatic Soft Tissue Sarcoma (STS)
  • 16.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in Japan
    • 16.2.1. Market Size of metastatic Soft Tissue Sarcoma (STS) by First-line of Therapies in Japan
    • 16.2.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Second-Line & Later Line Therapies in Japan

17. Market Drivers

18. Market Barriers

19. Appendix

  • 19.1. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight